GO:0002274Ontology (GO BP)GO biological process · ~241 member genes
Q-omics provides the Myeloid leukocyte activation (GO:0002274) pathway profile, scoring each patient from the combined activity of its roughly 241 member genes. Pathway activity is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, the pathway is differentially active in 13, with the highest sampling consensus in COAD. Additionally, pathway RNA activity shows 36,155 significant cross-omics associations, again with the highest sampling consensus in STAD. Together, these results highlight HNSC, COAD, and STAD as cancer lineages where the pathway shows reproducible signals across outcome, tissue activity, and molecular association analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns. Pathway-against-pathway and pathway-against-mutation comparisons are not available for ontology entities.
Survival associations
This table summarizes Myeloid leukocyte activation survival associations by molecular data type. RNA-level pathway activity shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each layer.
This table ranks reproducible pathway activity–survival associations across cancer types. High Myeloid leukocyte activation activity shows favorable associations in HNSC, SKCM and LUAD, but unfavorable associations in UVM, LGG and KIRC. In the HNSC Kaplan–Meier curve the low-activity group declines faster, consistent with the favorable association (log-rank p < 0.001). HNSC ranks highest by sampling consensus for Myeloid leukocyte activation.
This table summarizes Myeloid leukocyte activation tumor–normal activity differences by data type. RNA-level activity shows significant tumor–normal differences in 13 cancer types, while mass-spec protein activity shows differences in 2. The strongest signals are in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal activity differences for the pathway. A positive fold-change indicates higher activity in tumor tissue. The pathway shows higher tumor activity across KIRC and lower tumor activity in COAD, LUAD, KICH, LUSC and LIHC. In the COAD box plot, normal samples show higher pathway activity than tumor samples (log2 FC = −0.028, t-test p < 0.001).
This table shows molecular features associated with Myeloid leukocyte activation pathway activity in patient tissues and cancer cell lines. In patient samples, pathway activity is most strongly linked to RNA and protein features, with the largest associated set in STAD. In cancer cell lines, RNA-expression features and functional dependencies dominate, with the largest set in OESOPHAGUS.
